Yahoo Finance15d
Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Also, Viking was seen by some as a potential acquisition target for Merck. However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and ...
Nasdaq14d
Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and potentially formidable) competitor for Viking and greatly reduced the ...
The Motley Fool26d
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
The company has penned a deal to develop a potential GLP-1 weight loss therapy, HS-10535, with China-based Hansoh Pharma. It signed a similar licensing deal with LaNova Medicines for the ...
americanbazaaronline.com22d
Big Pharma turns to China for future deals
Merck & Co. signed an exclusive global license agreement with Chinese pharmaceutical company Hansoh Pharma for HS-10535, an oral glucagon-like peptide-1 (GLP-1) receptor agonist being developed as ...